ECSP055960A - Formulaciones parenterales de un péptido para el tratamiento de lupus sistémico eritematoso - Google Patents
Formulaciones parenterales de un péptido para el tratamiento de lupus sistémico eritematosoInfo
- Publication number
- ECSP055960A ECSP055960A EC2005005960A ECSP055960A ECSP055960A EC SP055960 A ECSP055960 A EC SP055960A EC 2005005960 A EC2005005960 A EC 2005005960A EC SP055960 A ECSP055960 A EC SP055960A EC SP055960 A ECSP055960 A EC SP055960A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- solution
- temperature
- peptide
- provides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 5
- 206010025135 lupus erythematosus Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 11
- 239000008135 aqueous vehicle Substances 0.000 abstract 5
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 abstract 3
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 abstract 3
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 abstract 3
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 abstract 3
- HWCBFXAWVTXXHZ-NYVOZVTQSA-N Trp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HWCBFXAWVTXXHZ-NYVOZVTQSA-N 0.000 abstract 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 abstract 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 abstract 3
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 238000004108 freeze drying Methods 0.000 abstract 2
- 238000012792 lyophilization process Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 159000000021 acetate salts Chemical group 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- -1 hepta-sulfobutyl Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
SUMARIO DE LA INVENCIÓN La presente invención provee una composición farmacéutica que comprende: Un vehículo acuoso; de 0.1 mg/ml a 20 mg/ml de la composición de una sal farmacéuticamente aceptable de un péptido que tiene la fórmula estructural NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooh (SEC ID NO:1). Una ß ciclodextrina sustituída en una cantidad efectiva para disolver el péptido en el vehículo acuoso, en donde la composición tiene un pH entre 4 y 9. La invención sujeto también provee una composición farmacéutica que también comprende: Un vehículo acuoso; de 0.1 mg/ml a 20 mg/ml de la composición de la sal de acetato de un péptido que tiene la fórmula estructural NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooh (SEC ID NO:1); y de 70 mg/ml a 170 mg/ml de la composición de hepta-sulfobutileter-ß-ciclodextrina, en donde el péptido y el hepta-sulfobutileter-ß-ciclodextrina se disuelven en el vehículo acuoso; y en donde la solución tiene un pH entre 6.5 y 8.5. La invención sujeto también provee un método para aliviar los síntomas del lupus sistémico eritematoso (SLE) en un sujeto humano que comprende administrar al sujeto humano cualquiera de las composiciones farmacéuticas anteriores en una cantidad efectiva para aliviar los síntomas del SLE en el sujeto humano. La invención sujeto también provee un procedimiento de fabricación de la composición farmacéutica anterior que comprende los siguientes pasos: a) Preparación de una solución de un ß-ciclodextrina sustituída en un vehículo acuoso a una concentración predeterminante; b) Agregar una cantidad predeterminante de una sal farmacéuticamente aceptable del péptido NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooh (SEC ID NO:1)a la solución del paso a); c) Ajustar el pH de la solución del paso b) hasta que el péptido se disuelva en la solución; y d) si es necesario, ajustar el pH de la solución del paso c) a un pH de 4-9, de esa manera fabricar la composición farmacéutica. La invención sujeto también provee un procedimiento de liofilización de la composición farmacéutica anterior, que comprende los pasos de: a) Reducir la temperatura de una composición farmacéutica a -40°C; b) Sostener la temperatura a -40°C por un tiempo predeterminado; c) Elevar la temperatura de la solución a 20°C; d) Sostener la temperatura a 20°C por un tiempo predeterminado; y e) Reducir la presión a 10µbarias, de esa manera liofilizar la composición farmacéutica. La invención sujeto también provee un procedimiento de liofilización de la composición farmacéutica anterior, que comprende los pasos de: a) Reducir la temperatura de la composición farmacéutica a -45°C; b) Sostener la temperatura a -45°C por un tiempo predeterminado; c) Elevar la temperatura de la solución a -20°C; d) Elevar la temperatura de la solución a 25°C; y e) Sostener la temperatura a 25°C por un tiempo predeterminado, de esa manera liofilizar la composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43995003P | 2003-01-14 | 2003-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP055960A true ECSP055960A (es) | 2006-04-19 |
Family
ID=32771763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005005960A ECSP055960A (es) | 2003-01-14 | 2005-08-11 | Formulaciones parenterales de un péptido para el tratamiento de lupus sistémico eritematoso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7294687B2 (es) |
| EP (1) | EP1587525A4 (es) |
| JP (1) | JP2006516034A (es) |
| KR (1) | KR20050100616A (es) |
| CN (1) | CN1761477A (es) |
| AU (1) | AU2004206844A1 (es) |
| BR (1) | BRPI0406737A (es) |
| CA (1) | CA2513331A1 (es) |
| CO (1) | CO5640149A2 (es) |
| CR (1) | CR7936A (es) |
| EA (1) | EA008438B1 (es) |
| EC (1) | ECSP055960A (es) |
| MX (1) | MXPA05007552A (es) |
| NO (1) | NO20053761L (es) |
| NZ (1) | NZ541659A (es) |
| UA (1) | UA83816C2 (es) |
| WO (1) | WO2004064788A2 (es) |
| ZA (1) | ZA200506205B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141647A0 (en) | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| KR20050100617A (ko) * | 2003-01-14 | 2005-10-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형 |
| JP2006516034A (ja) * | 2003-01-14 | 2006-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 全身性エリテマトーデスを治療するためのペプチドの非経口製剤 |
| DE102004043750A1 (de) * | 2004-09-10 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| WO2008073448A2 (en) * | 2006-12-12 | 2008-06-19 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations and methods for making the same |
| EP2121139B1 (en) * | 2007-01-16 | 2012-10-10 | BiPar Sciences, Inc. | Formulations for cancer treatment |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| WO2013123254A1 (en) | 2012-02-15 | 2013-08-22 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| KR102112119B1 (ko) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| PT3183295T (pt) | 2014-08-22 | 2023-11-03 | Cydex Pharmaceuticals Inc | Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas |
| CA3047706A1 (en) | 2017-01-05 | 2018-07-12 | Yeda Research And Development Co. Ltd. | Peptides for treating sjogren's syndrome |
| CN110960442B (zh) * | 2019-12-17 | 2023-03-31 | 珠海冀百康生物科技有限公司 | 一种多肽包封物的制备方法 |
| EP4297727A4 (en) * | 2021-02-24 | 2024-12-25 | NBO Pharma Inc. | METHODS AND THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF IDIOPATHIC INTRACRANIAL HYPERTENSION AND FACIAL PAIN |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60184098A (ja) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | 新規なペプチド及びこれを有効成分とする利尿剤 |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| US6613536B1 (en) | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US20020054872A1 (en) | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| IL120503A0 (en) | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| WO1999031066A1 (en) | 1997-12-18 | 1999-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridones as src family sh2 domain inhibitors |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US7114005B2 (en) | 2002-02-05 | 2006-09-26 | Cisco Technology, Inc. | Address hopping of packet-based communications |
| JP2006516034A (ja) * | 2003-01-14 | 2006-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 全身性エリテマトーデスを治療するためのペプチドの非経口製剤 |
| KR20050100617A (ko) * | 2003-01-14 | 2005-10-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형 |
-
2004
- 2004-01-14 JP JP2006500958A patent/JP2006516034A/ja not_active Withdrawn
- 2004-01-14 CN CNA2004800069919A patent/CN1761477A/zh active Pending
- 2004-01-14 BR BR0406737-1A patent/BRPI0406737A/pt not_active IP Right Cessation
- 2004-01-14 US US10/758,572 patent/US7294687B2/en not_active Expired - Lifetime
- 2004-01-14 EP EP04702214A patent/EP1587525A4/en not_active Withdrawn
- 2004-01-14 MX MXPA05007552A patent/MXPA05007552A/es active IP Right Grant
- 2004-01-14 NZ NZ541659A patent/NZ541659A/en unknown
- 2004-01-14 EA EA200501129A patent/EA008438B1/ru not_active IP Right Cessation
- 2004-01-14 KR KR1020057013097A patent/KR20050100616A/ko not_active Withdrawn
- 2004-01-14 UA UAA200507998A patent/UA83816C2/ru unknown
- 2004-01-14 WO PCT/US2004/000955 patent/WO2004064788A2/en not_active Ceased
- 2004-01-14 AU AU2004206844A patent/AU2004206844A1/en not_active Abandoned
- 2004-01-14 CA CA002513331A patent/CA2513331A1/en not_active Abandoned
-
2005
- 2005-08-03 ZA ZA200506205A patent/ZA200506205B/en unknown
- 2005-08-08 NO NO20053761A patent/NO20053761L/no not_active Application Discontinuation
- 2005-08-09 CR CR7936A patent/CR7936A/es unknown
- 2005-08-10 CO CO05079319A patent/CO5640149A2/es not_active Application Discontinuation
- 2005-08-11 EC EC2005005960A patent/ECSP055960A/es unknown
-
2007
- 2007-11-12 US US11/985,068 patent/US20080287366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080287366A1 (en) | 2008-11-20 |
| MXPA05007552A (es) | 2006-05-19 |
| EA200501129A1 (ru) | 2006-02-24 |
| EA008438B1 (ru) | 2007-06-29 |
| CA2513331A1 (en) | 2004-08-05 |
| KR20050100616A (ko) | 2005-10-19 |
| ZA200506205B (en) | 2006-12-27 |
| UA83816C2 (ru) | 2008-08-26 |
| EP1587525A4 (en) | 2008-09-10 |
| BRPI0406737A (pt) | 2005-12-20 |
| AU2004206844A1 (en) | 2004-08-05 |
| NO20053761L (no) | 2005-10-12 |
| WO2004064788A3 (en) | 2005-03-24 |
| JP2006516034A (ja) | 2006-06-15 |
| NZ541659A (en) | 2007-05-31 |
| EP1587525A2 (en) | 2005-10-26 |
| CR7936A (es) | 2006-05-31 |
| NO20053761D0 (no) | 2005-08-08 |
| US7294687B2 (en) | 2007-11-13 |
| WO2004064788A2 (en) | 2004-08-05 |
| CO5640149A2 (es) | 2006-05-31 |
| US20040180059A1 (en) | 2004-09-16 |
| CN1761477A (zh) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP055960A (es) | Formulaciones parenterales de un péptido para el tratamiento de lupus sistémico eritematoso | |
| KR101775929B1 (ko) | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 | |
| HUT53281A (en) | Compositions absorbing through mycosa | |
| CN118203658A (zh) | 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法 | |
| AR063201A1 (es) | Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas | |
| NZ238240A (en) | Ophthalmic compositions comprising c 20+ amino steroids as the active agent (the amino substituents are suitably heterocyclic rings); methods of treatment and preparation, commercial packages | |
| WO2003011224A3 (en) | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| Chen et al. | Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery | |
| CN110876259B (zh) | 注射用组合物 | |
| EP3013853A1 (en) | New use for jnk inhibitor molecules for treatment of various diseases | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| Tavornvipas et al. | Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor | |
| CN111939267A (zh) | 抗体-药物偶联物制剂、制备方法及应用 | |
| CN113116812A (zh) | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 | |
| ATE289801T1 (de) | Verabreichungssystem für wasserunlösliche arzneistoffe | |
| US20240398764A1 (en) | Methods of treating diseases associated with senescent cell accumulation | |
| JP2001500876A (ja) | 液体形態の改良された安定性を有するコルチコトロピン放出因子の医薬製剤 | |
| KR101286802B1 (ko) | 아자시티딘의 전―동결건조 제제, 아자시티딘의 동결건조 제제 및 이의 제조방법 | |
| US10314880B2 (en) | Composition comprising bortezomib | |
| JPH11240835A (ja) | 安定なプロスタグランジンｅ１−含有注射剤組成物 | |
| JP5102949B2 (ja) | プロゲステロンを有する新規の注入可能製剤 | |
| JP2005523329A (ja) | カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物 | |
| JP2011001269A (ja) | 紫外線誘発皮膚炎又は一次刺激性皮膚炎の予防又は治療用外用剤 | |
| JP6931257B2 (ja) | レバミピドを含有する新規ドライアイ治療用点眼組成物及びその可溶化及び安定化方法 |